Dasatinib Approved for Treatment of Certain Pediatric Patients
January 3rd 2019The FDA has approved dasatinib (Sprycel, Briston-Myers Squibb) tablets in combination with chemotherapy for the treatment of pediatric patients ≥1 year of age with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Read More
Dasatinib Receives FDA Approval for Pediatric Ph+ Acute Lymphoblastic Leukemia
January 3rd 2019The FDA has approved dasatinib (Sprycel) tablets in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
Read More
Study: Genetic Risk Variant Linked to Astrocytes Increases Risk of MS
January 2nd 2019Study results show a genetic risk variant on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis.
Read More